作者
G Lenz, G Wright, SS Dave, W Xiao, J Powell, H Zhao, W Xu, B Tan, N Goldschmidt, Javeed Iqbal, J Vose, M Bast, Kai Fu, DD Weisenburger, Timothy Charles Greiner, James O Armitage, A Kyle, L May, RD Gascoyne, JM Connors, G Troen, H Holte, S Kvaloy, D Dierickx, G Verhoef, J Delabie, EB Smeland, P Jares, A Martinez, A Lopez-Guillermo, E Montserrat, E Campo, RM Braziel, TP Miller, LM Rimsza, JR Cook, B Pohlman, J Sweetenham, RR Tubbs, RI Fisher, E Hartmann, A Rosenwald, G Ott, H-K Muller-Hermelink, D Wrench, TA Lister, ES Jaffe, WH Wilson, WC Chan, LM Staudt
发表日期
2008/11/27
期刊
New England Journal of Medicine
卷号
359
期号
22
页码范围
2313-2323
出版商
Massachusetts Medical Society
简介
Background
The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved the survival of patients with diffuse large-B-cell lymphoma. Whether gene-expression signatures correlate with survival after treatment of diffuse large-B-cell lymphoma is unclear.
Methods
We profiled gene expression in pretreatment biopsy specimens from 181 patients with diffuse large-B-cell lymphoma who received CHOP and 233 patients with this disease who received R-CHOP. A multivariate gene-expression–based survival-predictor model derived from a training group was tested in a validation group.
Results
A multivariate model created from three gene-expression signatures — termed “germinal-center B-cell,” “stromal-1,” and “stromal-2” — predicted survival both in patients who received CHOP and patients who received R …
引用总数
学术搜索中的文章
G Lenz, G Wright, SS Dave, W Xiao, J Powell, H Zhao… - New England Journal of Medicine, 2008